Roche acquisition of InterMune highlights Big Pharma interest in rare diseases
$8.3-billion deal is Roche’s biggest since acquiring Genentech in 2009
Roche Group (Basel, Switzerland) is paying a hefty 38% premium on a company whose stock price was already shooting upward after a successful clinical trial announced last spring for pirfenidone (marketed already outside the US as Esbriet) for idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease. InterMune (Brisbane, CA) postings indicate that the rare disease affects 50,000-70,000 patients in the US, with 15,000-20,000 new cases diagnosed annually.
Roche already markets several products (brought along with Genentech) for lung disease: Xolair, for asthma, and Pulmozyme for cystic fibrosis. So there’s a logic that complementary sales/marketing efforts for those drugs can be used for pirfenidone.
In July, FDA granted pirfenidone breakthrough-drug status, which can accelerate its final approval. That date, if it happens, is already set at Nov. 23, 2014.
In announcing the acquisition, Severin Schwan, CEO of Roche, noted that the company “looks forward to welcoming InterMune employees into the Roche Group;” other reported statements indicate the company will strive to keep InterMune staff relatively whole, in an effort to make the commercialization as smooth as possible in the US and to continue the drug development work going on within InterMune.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
